Connect with us
European Gaming Congress 2024

Latest News

Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs

Published

on

HERZLIYA, Israel and CALGARY, AB, June 11, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the success and conclusion of a preliminary safety evaluation of Innocan’s single injection and sustained-release LPT-CBD conducted on minipigs. The animals demonstrated excellent drug tolerance and did not exhibit any drug-related adverse events.

 

 

Recognized by the FDA as an excellent model for toxicology, small breeds of miniature domestic pigs known as minipigs share strong similarities with humans in crucial aspects such as drug metabolism, skin structure, genetics, and physiological mechanisms. In this preliminary safety study, minipigs received a single subcutaneous injection of LPT-CBD and were closely monitored for pharmacokinetics and basic safety parameters over one month. Encouragingly, the animals all exhibited good drug tolerance and did not manifest any drug-related adverse reactions.

“We are thrilled with these findings, which further underpin the safety profile of LPT-CBD following a single injection,” commented Dr. Eyal Kalo, the R&D Director of Innocan Pharma. “With each new data point collected for LPT-CBD, we make significant strides in our quest to revolutionize patient care through sustained-release therapy. Our efforts to continuously gather data to fully characterize LPT-CBD are paramount in our journey towards its ultimate approval.”

Advertisement
Stake.com

Professor Chezy Barenholz the CSO of Innocan Pharma added, “These results are immensely gratifying and hold significant promise as they highlight the characteristics of LPT-CBD in a physiological setting similar to humans.”

The study involved administering three ascending doses of LPT-CBD via subcutaneous injection in minipigs, followed by comprehensive monitoring of pharmacokinetics and safety parameters for 28 days. Throughout the study, the minipigs demonstrated excellent drug tolerance, as evidenced by blood clinical parameters whithin normal range, healthy appetite, and normal behavior. These findings are consistent with prior safety evaluations conducted with LPT-CBD on diverse animal models including goats and dogs, affirming the drug’s favorable tolerability profile following both single and repeated use.

Grant of Restricted Share Units                                                                                                 

The Company has granted an aggregate of 290,000 restricted share units (each, an “RSU“) to consultants. Each RSU entitles the recipient to receive one common share of the Company (a “Common Share“) on vesting. A total of 150,000 RSUs vest on May 30, 2024, and 140,000 RSUs vest on September 30, 2024. The RSUs and the underlying Common Shares are subject to a statutory hold period of four months and one day expiring on October 1, 2024.

Innocan also announces that it granted 2,380,000 stock options to employees and consultants to the Company. These options have a strike price of $0.28, with various vesting periods up to 12 months. All options expire on May 30, 2029.

Advertisement
Stake.com

About Innocan Pharma:

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/

Contact Information:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
[email protected] 

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Advertisement
Stake.com

Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

Advertisement
Stake.com

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-announces-successful-preliminary-safety-evaluation-of-lpt-cbd-in-minipigs-302169232.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

Global Talent Partner Phaidon International Strengthens Board With New CPO

Published

on

NEW YORK, June 26, 2024 /PRNewswire/ — Phaidon International, the professional services firm specializing in securing business-critical talent, is pleased to announce the appointment of Mark Norton as the new Chief People Officer (CPO). This strategic hire reflects Phaidon International’s commitment to accelerating global growth and delivering outstanding results for clients worldwide.

 

 

Mark brings a wealth of knowledge and a proven track record in people strategy. With over 20 years of experience, he has held key leadership roles at Campari Group and Broadcom where he played a critical role in driving results through strategic talent initiatives, modernizing the operating model for commercial success.

“We’re thrilled to have Mark Norton join our executive team,” said Harry Youtan, CEO of Phaidon International.

Advertisement
Stake.com

“Mark’s expertise will support our continuing goals to expand our global reach and deliver exceptional results for our clients. Mark’s leadership perfectly aligns with our mission to empower businesses and individuals to achieve their full potential.”

As Chief People Officer, Mark will unite Talent, Human Resources and Training functions under one single roof, to build and execute a strategy aligned to a high-performance growth organization. His leadership will be instrumental in accelerating the business as Phaidon International looks to continue its ambitious growth plans.

“I am excited to join Phaidon International and contribute to its vision,” said Mark.

“I look forward to working with the team to develop forward-thinking people strategies that not only attract and retain top talent but also drive the company’s success in the marketplace.”

This appointment comes at a pivotal time for Phaidon International as it continues to expand its services and solutions to meet the evolving needs of businesses in today’s competitive landscape, strengthening its position as a trusted talent partner and driving growth for clients and professionals globally.

Advertisement
Stake.com

For more information about Phaidon International and its services, please visit phaidoninternational.com.

About Phaidon International

Phaidon International identifies, sources, and delivers business-critical talent to the most innovative industries in the world. Delivering its capabilities through a deliberately curated group of 6 brands, each one specializes in the following industries, where a relentless supply-demand imbalance exists:

Selby Jennings – Financial Sciences & Services
LVI Associates – Energy & Infrastructure
DSJ Global – Supply Chain
EPM Scientific – Life Sciences
Glocomms – Technology
Larson Maddox – Regulatory & Legal

Today, Phaidon International is proud to deliver excellence to clients in over 60 countries, winning over 50 independent awards along the way. Phaidon International is backed by Further Global.

Advertisement
Stake.com

Photo: https://mma.prnewswire.com/media/2448516/Phaidon_International_Mark_Norton.jpg
Logo: https://mma.prnewswire.com/media/1880120/Phaidon_Logo.jpg

 

Phaidon International Logo

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/global-talent-partner-phaidon-international-strengthens-board-with-new-cpo-302183208.html

Continue Reading

Latest News

DAR GLOBAL SETS A NEW BENCHMARK IN LUXURY HOSPITALITY WITH LAUNCH OF THE $500 MILLION TRUMP INTERNATIONAL OMAN IN AIDA

Published

on

DUBAI, UAE, June 26, 2024 /PRNewswire/ — Dar Global, the luxury international real estate developer, introduces Trump International Oman at its expansive AIDA project, one of the world’s largest premium mixed-use real estate developments.

 

 

Valued at $500 million, this development includes a luxury hotel, hanging suites, furnished villas, and apartments serviced by the hotel. It features a 18-hole Championship golf course, a members-only club, and the Cliff Hanging Night Club. Opening in December 2028, the 140-key, 5-star hotel complex is beachfront, offering guests complimentary private beach access.

AIDA is a joint venture between Dar Global and the Trump Organization, in partnership with Omran Group, Oman’s executive arm for tourism development. Situated atop a hill over 100 meters high, AIDA boasts panoramic views of rocky canyons and endless beaches.

Advertisement
Stake.com

Ziad El Chaar, CEO, Dar Global, said: “The launch of Trump International Oman in AIDA, signifies a significant leap in our endeavor to build an unmatched hospitality portfolio in the world’s most coveted destinations. Reflecting Dar Global and Trump Organization’s commitment to excellence, this landmark establishment not only sets new standards in international hospitality but also advances Oman’s tourism vision, drawing in a broader audience while stimulating domestic tourism.”

Eric Trump, EVP, The Trump Organization, said: “In collaboration with Dar Global, we proudly introduce Trump International Oman in AIDA, ushering in a new era of style, service, and exclusivity with the renowned Trump standard. This partnership reflects our shared dedication to crafting iconic luxury experiences for discerning travelers and investors, enhancing Oman’s prominence as a premier global destination.”

Unique to Trump International in Oman are picturesque hanging suites with private pools and ensuite bathrooms offering sweeping views. Complementing the golfing lifestyle are a training academy and a members-only club with exclusive amenities for networking and social events. The Cliff Hanging Night Club, a first in the ME, offers an unrivalled setting for bespoke events and celebrations. Other amenities include diverse dining options, banqueting and meeting facilities, and an expansive SPA.

Disclaimer: Trump International Oman is not owned, developed or sold by The Trump Organization or any of their current or former principals or affiliates. Dar Al Arkan Property Development SPC, the owner and developer of the property, uses the “Trump” name and mark under license, which license may be terminated or revoked according to its terms.

Photo – https://mma.prnewswire.com/media/2448900/Dar_Global.jpg

Advertisement
Stake.com

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/dar-global-sets-a-new-benchmark-in-luxury-hospitality-with-launch-of-the-500-million-trump-international-oman-in-aida-302183369.html

Continue Reading

Latest News

Rising Concerns in Food Security: How Agritech and Food Companies Are Responding

Published

on

USA News Group Commentary
Issued on behalf of Bee Vectoring Technologies International Inc.

VANCOUVER, BC, June 26, 2024 /PRNewswire/ — USA News Group – Citizens of Portland were covered in smoke this week, after a 4-alarm grease fire destroyed the Shin Shin food factory. This incident followed another fire earlier in June that broke out at the Champlain Beef meat processing plant which is situated between the border of Upstate New York and Vermont, while another chicken factory in Illinois erupted in flames at the beginning of the month. While these two tragedies likely won’t make a dent in the overall food security of the United States, they do present a rising trend of concern towards where our food comes from. At every level, new research is finding ways to keep the food supply chain going, with new research from Carnegie Science showing that adopting new approaches to fertilizers can pave the way for more sustainable, resilient food sources. In the private sector, some of the top agritech companies continue to make major strides in their work to secure the food of the future, including new developments from Bee Vectoring Technologies International Inc. (CSE: BEE) (OTCQB: BEVVF), AGCO Corporation (NYSE: AGCO), Lamb Weston Holdings, Inc. (NYSE: LW), Bunge Global SA (NYSE: BG), and Conagra Brands, Inc. (NYSE: CAG).

One innovation that’s gaining a lot of momentum is the concept of using commercially-reared bees to deliver biological pesticide alternatives directly to crops. It’s a method that some experts say has the potential to transform the $250 billion crop protection and fertilizer industry.

At the forefront of this innovation is Bee Vectoring Technologies International Inc. (BVT) (CSE: BEE) (OTCQB: BEVVF), which focuses on biological agricultural products (“biologicals”) that aim to replace chemical pesticides and fertilizers. Its method of utilizing bees to deliver necessary biologicals has already received approval from the EPA on two occasions, in 2019 and 2021.

According to DataHorizzon Research, the biologicals sector is already experiencing significant growth, with a projected compound annual growth rate (CAGR) of 13.3%, expected to reach a market size of US$45.3 billion by 2032.

Advertisement
Stake.com

The latest win for BVT is its announcement today of a partnership with the newly formed €8 billion (~US$8.56 billion) company Syensqo, a science and innovation pioneer in specialty chemicals and materials. As per the deal, BVT and Synensqo through an R&D agreement will develop BVT’s proprietary biological control agent Clonostachys rosea strain CR-7 (CR-7) into a seed treatment formulation for the multi-billion soybean market.

“Collaborating with Syensqo is a huge extension of our R&D efforts,” said Ashish Malik, CEO of BVT. “Their large team of formulation chemists and microbiologists will enable us to get to market with a strong seed treatment formulation much faster. Fast-tracking BVT into soybean crops through the well-established seed coating market will expand the Company’s addressable market beyond bee vectoring, bringing CR-7 to more growers by tapping into approaches they are already familiar with. BVT’s go-to market strategy is to commercialize this new CR-7 seed treatment product for sale through large agriculture suppliers, partners and distributors.”

The partnership comes after BVT recently achieved significant progress with CR-7, particularly as a seed treatment for soybeans. Recent US trials showed wherever CR-7 was applied, the results outperformed the base seed treatment 81% of the time. This is in addition to previous successful trials in 2021, which also showed CR-7 to be an effective treatment against Sudden Death Syndrome (SDS), a huge challenge for soybean growers.

BVT has expanded its corporate partnerships, leading to international trials and wider use of CR-7. A Michigan State University trial demonstrated CR-7’s effectiveness, reducing early disease infection and fungal diseases by over 90%, matching traditional chemical treatments.

In the past year, BVT has initiated trials in Spain, Mexico, and South Africa, and made its first sale of CR-7 to BioSafe Systems. Encouraged by positive trial results, BVT plans to conduct further trials to confirm CR-7’s effectiveness.

Advertisement
Stake.com

Today is also the launch of the annual Tech Days in North America event from AGCO Corporation (NYSE: AGCO). The event will highlight AGCO’s commitment to farmer-focused solutions for the mixed fleet.

“Managing a farm is complicated, managing the right machine and technology for the job shouldn’t be,” said Eric Hansotia, Chairman, President and CEO of AGCO. “AGCO is unique in offering differentiated equipment brands to serve all farmers’ needs and the only company that can effectively retrofit almost any make or model of equipment with technology that will lead to higher yields with fewer inputs. This is how we have consistently put Farmers First for years.”

Embedded within AGCO’s entire portfolio are precision agriculture and clean technology solutions designed to help farmers sustainably feed the world now and in the future. AGCO Finance, the company’s financing arm, also focuses on future growth by collaborating with dealers globally to offer farmers customized and flexible financing solutions.

Potato processor Lamb Weston Holdings, Inc. (NYSE: LW) recently reached a settlement with Oregon regulators over wastewater violations. However, the potato giant is now also facing a securities lawsuit that claims Lamb Weston hid tech problems that cost millions. However, those challenges aside, Lamb Weston is persevering with new partnerships and innovation, including a newly announced partnership with foodservice company ILG Food Group to better serve the Swedish Mediterranean foodservice market. Lamb Weston and ILG Food Group have been partners for the Dutch and Belgian markets for years, and are now expanding their partnership to Sweden.

For the pet food market, Bunge Global SA (NYSE: BG) recently expanded into pea, faba protein concentrates through a new factory in Latvia, exclusively producing for Bunge and run by Golden Fields. Bunge’s new range of pea and faba protein concentrates offers several enhanced attributes, including 55% to 70% protein content, non-GMO and allergen-free labeling, a light color, and a finely powdered form. News of the agreement for Bunge came shortly after Golden Fields opened the plant-based facility, which cost €16 million (~US$17.1 million) to build.

Advertisement
Stake.com

Bunge highlights the sustainability benefits of its new protein concentrates, produced using crop-rotation practices and dry-fractionation methods that eliminate the need for water or solvents typically used in pulse protein production.

“Our new pea and faba protein concentrates are setting the bar for European-origin pulse proteins to help customers meet growth and sustainability needs across food and feed,” said the company on social media.

Packaged foods giant Conagra Brands, Inc. (NYSE: CAG) recently announced it’s advancing its artificial intelligence (AI) solutions through a human-centered approach that prioritizes responsible use of AI across the entire company. Done through a strategic collaboration with Microsoft and EY to enhance its IT, Supply Chain, R&D, Demand Science, Brand and Design operations.

“As we implement new solutions available to us through collaborations and emerging technologies, we are not only realizing measurable results now, but identifying opportunities for future growth,” said Azeem Kapadia, senior director of AI strategy at Conagra Brands. “These new digital capabilities will benefit our entire team, sharpen our focus and better shape how we operate and innovate throughout Conagra.”

Article Source: https://usanewsgroup.com/2024/05/06/the-buzz-on-eco-farming-how-bees-are-pioneering-the-future-of-crop-protection/ 

Advertisement
Stake.com

USA News Group
Editorial Staff

CONTACT:
USA NEWS GROUP
[email protected]
(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Bee Vectoring Technologies International Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Bee Vectoring Technologies International Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Bee Vectoring Technologies International Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares Bee Vectoring Technologies International Inc. at any time without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, we currently own shares of Bee Vectoring Technologies International Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

View original content:https://www.prnewswire.co.uk/news-releases/rising-concerns-in-food-security-how-agritech-and-food-companies-are-responding-302183344.html

Advertisement
Stake.com

Continue Reading
Advertisement
Stake.com
Advertisement

Latest news

Trending